Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Dendreon Corporation    

DENDREON CORPORATION
Mes dernières consult.
Most popular
  Report  
 SummaryNewsCalendarCompanyFinancials 
Company
Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer.The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a... 
More about the company
Latest news on DENDREON CORPORATION
2015Valeant Approved to Buy Dendreon Assets for $495 Million
DJ
2015Drugmaker Valeant close to buying Salix - source
RE
2015VALEANT SECURES FINANCING FOR POTENT : Bloomberg
RE
2015Energy Future Fights for Control of its Bankruptcy -- Week Ahead
DJ
2015DENDREON : Valeant to buy Dendreon's prostate cancer vaccine Provenge
RE
2014DENDREON CORPORATION : A New Combined Approach to Cancer Immunotherapy is Needed
AC
2014DENDREON CORPORATION : Bankruptcies, Breakouts, and Busts; What's Happening in B..
AC
2014MARKET SNAPSHOT : U.S. Stocks Eke Out Monday Gains; S&P 500, Dow Hit Records
DJ
2014MARKET SNAPSHOT : U.S. Stocks Eke Out Monday Gains; S&P 500, Dow Hit Records
DJ
2014MARKET SNAPSHOT : U.S. Stocks Eke Out Monday Gains; S&P 500, Dow Hit Records
DJ
More news
Sector news : Biotechnology & Medical Research - NEC
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Biotechnology & Medical Research - NEC
Income Statement Evolution
Managers
NameTitle
Craig R. Jalbert President, Secretary, Treasurer & Director
William Monteith Executive Vice President-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
DENDREON CORPORATION0
CELLTRION, INC.--.--%36 110
IQVIA HOLDINGS INC6.93%21 125
LONZA GROUP-7.82%18 606
INCYTE CORPORATION-6.91%18 063
NEKTAR THERAPEUTICS40.66%13 227